Non-formulary **risedronate (Actonel)** will be covered on the prescription drug benefit when the following criteria are met:

1. Documented trial and intolerance of alendronate tablets. Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment and/or do not require med discontinuation.

2. Dose change only: Patient previously met criteria and is already taking the drug.